A Phase 1 Study to Assess Safety, Tolerability, and Pharmacokinetics of PUR3100, a Novel Dry Powder Formulation of Dihydroergotamine for Oral Inhalation, in Healthy Adults.

被引：0

作者：

Wasilewski, M. ^{[1
]}

Bodie, S. ^{[1
]}

Gonzalez, Nelson A. ^{[1
]}

Clayton, R. ^{[1
]}

Curran, A. ^{[1
]}

机构：

[1] Pulmatrix Inc, 99 Hayden Ave,Suite 390, Lexington, MA USA

来源：

HEADACHE | 2023年 / 63卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P-05

引用

页码：114 / 115

页数：2

共 50 条

[21] A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens (RC-P) in Healthy Adults
Hernandez-Illas, Martha
Lin, Tong
Rey, Andres
Jenkins, Jack
Chandula, Reddy
Choi, Mi Rim
BLOOD, 2019, 134
[22] PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ENSIFENTRINE IN HEALTHY CHINESE ADULTS: A PHASE 1, OPEN-LABEL, SINGLE AND MULTIPLE DOSE STUDY
Meng, Haijin
Li, Xin
Chen, Charlie
Cheng, Cecilia
Zhang, Ping
Yuan, Chenchen Zhang
CHEST, 2024, 166 (04) : 4758A - 4758A
[23] A PHASE I ADAPTIVE DESIGN STUDY TO ASSESS SAFETY, TOLERABILITY AND PHARMACOKINETICS OF SINGLE ASCENDING ORAL DOSES OF GIC-1001 IN HEALTHY VOLUNTEERS.
Sayegh, L.
Rufiange, M.
Sadoune, A. Ait
Sicard, E.
Massicotte, J.
Lefebvre, M.
Colin, P.
Ranger, M.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S63 - S64
[24] Phase 1 study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of PGN-EDODM1 in adults with myotonic dystrophy type 1 (DM1)
Shoskes, J.
Larkindale, J.
Cormier, J.
Hand, H.
Vacca, S.
Lonkar, P.
Holland, A.
Garg, B.
Foy, J.
Mellion, M.
NEUROMUSCULAR DISORDERS, 2023, 33 : S156 - S156
[25] Pharmacokinetics, Safety, and Tolerability of Oxfendazole in Healthy Adults in an Open-Label Phase 1 Multiple Ascending Dose and Food Effect Study
Bach, Thanh
Galbiati, Shirley
Kennedy, Jessie K.
Deye, Gregory
Nomicos, Effie Y. H.
Codd, Ellen E.
Garcia, Hector H.
Horton, John
Gilman, Robert H.
Gonzalez, Armando E.
Winokur, Patricia
An, Guohua
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (11)
[26] PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF OXFENDAZOLE IN HEALTHY ADULTS IN AN OPEN LABEL PHASE 1 MULTIPLE ASCENDING DOSE AND FOOD EFFECT STUDY.
Bach, T.
Galbiati, S.
Kennedy, J.
Deye, G.
Nomicos, E.
Codd, E.
Garcia, H.
Horton, J.
Gilman, R.
Gonzalez, A.
Winokur, P.
An, G.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 109 : S17 - S17
[27] A randomized, placebo-controlled, dose-escalation, phase 1 study of the safety and pharmacokinetics of amphotericin B inhalation powder in healthy subjects
Marcantonio, Annette
Kugler, Alan R.
Sahner, David
Mufti, Nina
Lee, Jonathan D.
Samford, Lori K.
Eldon, Michael A.
BLOOD, 2007, 110 (11) : 324B - 324B
[28] ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a Commercial Apomorphine Formulation: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Relative Bioavailability
Ramot, Yuval
Nyska, Abraham
Adar, Liat
Durlach, Cecile
Fishelovitch, Danny
Sacco, Giuseppe
Manno, Rosa Anna
Oren, Sheila
Perlstein, Itay
Yacobi-Zeevi, Oron
CNS DRUGS, 2018, 32 (05) : 443 - 454
[29] ND0701, A Novel Formulation of Apomorphine for Subcutaneous Infusion, in Comparison to a Commercial Apomorphine Formulation: 28-Day Pharmacokinetic Study in Minipigs and a Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Relative Bioavailability
Yuval Ramot
Abraham Nyska
Liat Adar
Cecile Durlach
Danny Fishelovitch
Giuseppe Sacco
Rosa Anna Manno
Sheila Oren
Itay Perlstein
Oron Yacobi-Zeevi
CNS Drugs, 2018, 32 : 443 - 454
[30] A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects
Cohen-Barak, Orit
Weiss, Sivan
Rasamoelisolo, Michele
Faulhaber, Nicola
Yeung, Paul P.
Loupe, Pippa S.
Yoon, Esther
Gandhi, Mohit D.
Spiegelstein, Ofer
Aycardi, Ernesto
CEPHALALGIA, 2018, 38 (13) : 1960 - 1971

← 1 2 3 4 5 →